Joint GARDP/DNDi statement at 74th World Health Assembly

  29 May 2021

We thank WHO for the comprehensive report and its support, together with funders and partners, to GARDP to develop new treatments to address drug resistance.

The consequences of COVID-19 should encourage investment and international cooperation to prepare for and address the on-going impacts of antimicrobial resistance. The growth of drug-resistant infections is a silent pandemic. If left unchecked, humanity will be unable to treat common infections like pneumonia, infections in newborns or secondary bacterial infections in viral pandemics. Like COVID-19, drug-resistant bacteria can infect anyone, of any age, in any country. Unlike COVID-19, we can prepare now. The drug-resistant microbes are known, and meaningful change can be achieved with sufficient political will and resources.

Currently, the response is off course.

Further reading: GARDP
Author(s): GARDP
Effective Surveillance  


Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition


JSS University


Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!